

## **Jerome Alexandre**

---

### **Jérôme ALEXANDRE**

50 years old

N° RPPS 10001393767

Medical oncology service ; Hospital Group Cochin Broca Hôtel Dieu

### **QUALIFICATIONS**

June 2007 : Habilitation to direct researches (HDR, Habilitation à Diriger des Recherches), University Paris 5

November 2006 : PhD, University Paris 5

June 2001 : University diploma (DU) 'Soins Palliatifs et d'Accompagnement' (University Paris 11)

October 1999 : Medical Doctorate (MD, PhD) (University Paris 11)

October 1999 : DES (Diplôme d'Etudes Spécialisées) in Medical oncology

September 1998 : Master degree "Fundamental Basis of oncogenesis", university Paris 11

### **MEDICAL AND UNIVERSITY PROFESSIONAL ACTIVITIES**

Since 2012 : Professor of oncology – Hospital practitioner, Medical faculty Paris Descartes, University Sorbonne Paris Cité

Since december 2018 : Member of UMR-S1147 – « Personalized Medicine, Pharmacogenomics and therapeutic optimisation », University Paris Descartes, Pr P Laurent Puig, team « Translational research and microfluidics » (Dr V Taly).

2014-2018 : Member of the research team « Oxidative stress, cell proliferation and inflammation » Cochin Institute, INSERM U1016, CNRS UMR8104, Pr F Batteux,

Since 2014 : Head of UF « hospitalisation complète » of oncology service, 27 beds, + 25% of activity in 2 years.

Since 2010 : Head of the oncology coordination center (3C) of GH Cochin Broca Hôtel Dieu

2005-2006 : Post-doctoral researcher, MD Anderson Cancer Center, University of Texas (Houston, USA), Department of Molecular Pathology, Pr P. Huang.

### **TEACHING, MENTORING AND TRAINING ACTIVITIES**

Numeric referent for the Collège National des Enseignants de Cancérologie (CNEC), responsible of the setting up of the e-learning for the oncology DES

Continuing education and graduate training in gynecological oncology and anti-tumor agent pharmacology: DES of medical oncology, medical gynecology, and hospital pharmacy, oncology DESC, gynecological oncology DIU.

Training by research : supervision of university PhD students, Master 2 and medical resident for their MD doctorate.

Coordinator of the course « cancer biology » for the oncology DESC

### **RESEARCH ACTIVITIES**

Pharmacological modulation pharmacologique of intratumor oxidative metabolism : Team « Oxidative stress, cell proliferation and inflammation », Cochin Institute, SIRIC CARPEM

Identification of oxidative stress modulators with anti-tumor activity

Implication of the pathway NRF2 / KEAP1 / DJ1 of regulation of anti-oxidative responses defense in cell response to anti-tumor agents

Clinical Pharmacology of anti-tumor drugs, Integration of plasma measurements in the strategy of use of anti-tumor agents  
Clinical research and transfert in gynecologic cancers, Clinical and molecular characterization of ovarian and endometrium cancers subtypes.

### **UNIVERSITY RESPONSIBILITIES/ COMMISSIONS OF TRUST**

Participation to scientific comitees of several commissions, collaborative networks and associations for cancer research :

- SIRIC CARPEM University Paris Descartes-INSERM-APHP, network of oncology teams from HEGP, Cochin, Cordeliers and Necker
- Cooperative Group of clinical research on gynecologic cancers, GINECO
- ARC Foundation
- Martine Midy Foundation

### **PUBLICATIONS 2010-2019**

#### **Co-author of more than 120 publications indexed in medline**

Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. Jouinot A, Ulmann G, Vazeille C, Durand JP, Boudou-Rouquette P, Arrondeau J, Tlemsani C, Fournel L, Alifano M, Wislez M, Chapron J, Le Bris C, Mansuet-Lupo A, Damotte D, Neveux N, De Bandt JP, Alexandre J, Cynober L, Goldwasser F. Clin Nutr. 2019 Aug 10. pii: S0261-5614(19)30315-2. doi: 10.1016/j.clnu.2019.08.003. [Epub ahead of print]

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Noé G, Bellesoeur A, Golmard L, Thomas-Schoemann A, Boudou-Rouquette P, Tiako Meyo M, Puszkiel A, Arrondeau J, Alexandre J, Goldwasser F, Blanchet B, Vidal M. Cancers (Basel). 2019 May 31;11(6). pii: E762. doi: 10.3390/cancers11060762.

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. Delanoy N, Hardy-Bessard AC, Efsthathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier É, Deville JL, Goupil MG, Morales R, Thierry-Vuillemin A, Gavrikova T, Barthelemy P, Sella A, Fizazi K, Baciarello G, Fererro JM, Laguerre B, Verret B, Hans S, Oudard S. Eur Urol Oncol. 2018 Dec;1(6):467-475. doi: 10.1016/j.euo.2018.05.009. Epub 2018 Jun 8.

Multicentre analysis of intensity of care at the end-of-life in patients with advanced cancer, combining health administrative data with hospital records: variations in practice call for routine quality evaluation. Colombet I, Bouleuc C, Piolot A, Vilfaillot A, Jaulmes H, Voisin-Saltiel S, Goldwasser F, Vinant P; EFIQUAVIE study group. BMC Palliat Care. 2019 Apr 5;18(1):35. doi: 10.1186/s12904-019-0419-4.PMID:30953487

The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas. Beinse G, Just PA, Rance B, Izac B, Letourneur F, Saidu NEB, Chouzenoux S, Nicco C, Goldwasser F, Pasmant E, Batteux F, Borghese B, Alexandre J, Leroy K. PLoS One. 2019 Mar 25;14(3):e0214416. doi: 10.1371/journal.pone.0214416. eCollection 2019.

Dimethyl fumarate, a two-edged drug: Current status and future directions. Saidu NEB, Kavian N, Leroy K, Jacob C, Nicco C, Batteux F, Alexandre J. Med Res Rev. 2019 Sep;39(5):1923-1952. doi: 10.1002/med.21567. Epub 2019 Feb 12. Review.

[Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs]. Zaibet S, Vauchier C, Khoudour N, Roulleaux Dugage M, Korb-Savoldelli V, Alexandre J, Blanchet B, Goldwasser F, Thomas-Schoemann A, Bellesoeur A. Bull Cancer. 2018 Nov;105(11):1102-1109. doi: 10.1016/j.bulcan.2018.08.005. Epub 2018 Oct 8. French.

Low-Dose Abiraterone Regimen: Drug Monitoring Might Be the Key. Tiako Meyo M, Alexandre J, Goldwasser F, Blanchet B. *J Clin Oncol*. 2018 Oct 20;36(30):3061-3062. doi: 10.1200/JCO.2018.79.3174. Epub 2018 Sep 6. No abstract available.

A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. Blanchet B, Carton E, Alyamani M, Golmard L, Huillard O, Thomas-Schoemann A, Vidal M, Goldwasser F, Sharifi N, Alexandre J. *Pharmacol Res*. 2018 Oct;136:56-61. doi: 10.1016/j.phrs.2018.08.016. Epub 2018 Aug 22.

Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. Bellesoeur A, Thomas-Schoemann A, Allard M, Smadja D, Vidal M, Alexandre J, Goldwasser F, Blanchet B. *Crit Rev Oncol Hematol*. 2018 Sep;129:102-112. doi: 10.1016/j.critrevonc.2018.06.015. Epub 2018 Jul 9. Review.

[Integrated podiatrist care for prostate cancer patients treated with docetaxel: Feasibility and results]. Chabanol H, Huillard O, Prin L, Villeminey C, Rondeau A, Boudou-Rouquette P, Astorg F, Musenghesi B, Du Mortier C, Alexandre J, Goldwasser F. *Bull Cancer*. 2018 Dec;105(12):1173-1182. doi: 10.1016/j.bulcan.2018.06.005. Epub 2018 Aug 2. French.

BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. Tlemsani C, Pasmant E, Boudou-Rouquette P, Bellesoeur A, Even J, Larousserie F, Reyes C, Gentien D, Alexandre J, Vidaud M, Anract P, Leroy K, Goldwasser F. *Am J Med Sci*. 2018 Oct;356(4):404-407. doi: 10.1016/j.amjms.2018.04.015. Epub 2018 May 1. Review.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. Reis R, Labat L, Allard M, Boudou-Rouquette P, Chapron J, Bellesoeur A, Thomas-Schoemann A, Arrondeau J, Giraud F, Alexandre J, Vidal M, Goldwasser F, Blanchet B. *J Pharm Biomed Anal*. 2018 Sep 5;158:174-183. doi: 10.1016/j.jpba.2018.05.052. Epub 2018 Jun 1.

Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells. Bennett Saidu NE, Bretagne M, Mansuet AL, Just PA, Leroy K, Cerles O, Chouzenoux S, Nicco C, Damotte D, Alifano M, Borghese B, Goldwasser F, Batteux F, Alexandre J. *Oncotarget*. 2018 Jan 10;9(10):9088-9099. doi: 10.18632/oncotarget.24144. eCollection 2018 Feb 6.

The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages. Bougherara H, Némati F, Nicolas A, Massonnet G, Pugnière M, Ngô C, Le Frère-Belda MA, Leary A, Alexandre J, Meseure D, Barret JM, Navarro-Teulon I, Pèleguin A, Roman-Roman S, Prost JF, Donnadiou E, Decaudin D. *Oncotarget*. 2017 Oct 7;8(59):99950-99965. doi: 10.18632/oncotarget.21556. eCollection 2017 Nov 21.

Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. Cabel L, Blanchet B, Thomas-Schoemann A, Huillard O, Bellesoeur A, Cessot A, Giroux J, Boudou-Rouquette P, Coriat R, Vidal M, Saidu NEB, Golmard L, Alexandre J, Goldwasser F. *Fundam Clin Pharmacol*. 2018 Feb;32(1):98-107. doi: 10.1111/fcp.12327. Epub 2017 Nov 10.

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Bellesoeur A, Carton E, Alexandre J, Goldwasser F, Huillard O. *Drug Des Devel Ther*. 2017 Sep 21;11:2801-2811. doi: 10.2147/DDDT.S109640. eCollection 2017. Review.

ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype. Kossmann CM, Annereau M, Thomas-Schoemann A, Nicco-Overney C, Chéreau C, Batteux F, Alexandre J, Lemare F. *Tumour Biol*. 2017 Jul;39(7):1010428317716077. doi: 10.1177/1010428317716077.

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. *Eur J Cancer*. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.

Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Heidelberg V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S. Invest New Drugs. 2017 Aug;35(4):537. doi: 10.1007/s10637-017-0475-7. No abstract available.

Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. Heidelberg V, Goldwasser F, Kramkimel N, Jouinot A, Franck N, Arrondeau J, Guégan S, Mansuet-Lupo A, Alexandre J, Damotte D, Avril MF, Dupin N, Aractingi S. Invest New Drugs. 2017 Dec;35(6):842-847. doi: 10.1007/s10637-017-0476-6. Epub 2017 May 31.

A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. Puszkiel A, Plé A, Huillard O, Noé G, Thibault C, Oudard S, Goldwasser F, Vidal M, Alexandre J, Blanchet B. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jul 15;1058:102-107. doi: 10.1016/j.jchromb.2017.04.014. Epub 2017 Apr 5.

Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Heidelberg V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S. Invest New Drugs. 2017 Aug;35(4):436-441. doi: 10.1007/s10637-017-0464-x. Epub 2017 Apr 10. Erratum in: Invest New Drugs. 2017 Jun 9;.

Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France. Bonnet C, Boudou-Rouquette P, Azoulay-Rutman E, Huillard O, Golmard JL, Carton E, Noé G, Vidal M, Orvoen G, Chah Wakilian A, Villeminey C, Blanchet B, Alexandre J, Goldwasser F, Thomas-Schoemann A. Cancer Chemother Pharmacol. 2017 May;79(5):1051-1055. doi: 10.1007/s00280-017-3291-z. Epub 2017 Mar 30.

Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy. Vazeille C, Jouinot A, Durand JP, Neveux N, Boudou-Rouquette P, Huillard O, Alexandre J, Cynober L, Goldwasser F. Am J Clin Nutr. 2017 May;105(5):1139-1147. doi: 10.3945/ajcn.116.140434. Epub 2017 Mar 29.

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcmann G, Vielh P, Farace F, Valleix F, Podoll T, Kuramochi Y, Miyashita I, Hosono O, Dang NH, Ohnuma K, Yamada T, Kaneko Y, Morimoto C. Br J Cancer. 2017 Apr 25;116(9):1126-1134. doi: 10.1038/bjc.2017.62. Epub 2017 Mar 14.

Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. Puszkiel A, Noé G, Boudou-Rouquette P, Cossec CL, Arrondeau J, Giraud JS, Thomas-Schoemann A, Alexandre J, Vidal M, Goldwasser F, Blanchet B. J Pharm Biomed Anal. 2017 May 30;139:30-36. doi: 10.1016/j.jpba.2017.02.041. Epub 2017 Feb 24.

Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer. Henon C, Huillard O, Preta LH, Blanchet B, Goldwasser F, Alexandre J. Clin Genitourin Cancer. 2017 Jun;15(3):e493-e495. doi: 10.1016/j.clgc.2017.01.017. Epub 2017 Feb 1. No abstract available.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.

Resting energy expenditure in the risk assessment of anticancer treatments. Jouinot A, Vazeille C, Durand JP, Huillard O, Boudou-Rouquette P, Coriat R, Chapron J, Neveux N, De Bandt JP, Alexandre J, Cynober L, Goldwasser F. Clin Nutr. 2018 Apr;37(2):558-565. doi: 10.1016/j.clnu.2017.01.007. Epub 2017 Jan 19.

Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications. Saidu NE, Noé G, Cerles O, Cabel L, Kavian-Tessler N, Chouzenoux S, Bahuaud M, Chéreau C, Nicco C, Leroy K, Borghese B, Goldwasser F, Batteux F, Alexandre J. *Mol Cancer Ther*. 2017 Mar;16(3):529-539. doi: 10.1158/1535-7163.MCT-16-0405. Epub 2017 Jan 9.

Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. Bigot F, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tlemsani C, Chapron J, Huillard O, Cessot A, Vidal M, Alexandre J, Blanchet B, Goldwasser F.

A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma. Beinse G, Emile G, Cessot A, Boudou-Rouquette P, Huillard O, Saidu NE, Borghese B, Goldwasser F, Pujade Lauraine E, Alexandre J.

*Int J Gynecol Cancer*. 2016 Sep;26(7):1196-200. doi: 10.1097/IGC.0000000000000833.

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib. Noé G, Bellesoeur A, Thomas-Schoemann A, Rangarajan S, Naji F, Puzskiel A, Huillard O, Saidu N, Golmard L, Alexandre J, Goldwasser F, Blanchet B, Vidal M. *Oncotarget*. 2016 Oct 11;7(41):67507-67520. doi: 10.18632/oncotarget.11686.

Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. Boudou-Rouquette P, Tlemsani C, Blanchet B, Huillard O, Jouinot A, Arrondeau J, Thomas-Schoemann A, Vidal M, Alexandre J, Goldwasser F. *Expert Opin Drug Metab Toxicol*. 2016 Dec;12(12):1433-1444. Epub 2016 Aug 24. Review.

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D. *J Clin Oncol*. 2016 Aug 20;34(24):2881-7. doi: 10.1200/JCO.2016.66.9010. Epub 2016 Jul 11.

Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. Selle F, Emile G, Pautier P, Asmane I, Soares DG, Khalil A, Alexandre J, Lhommé C, Ray-Coquard I, Lotz JP, Goldwasser F, Tazi Y, Heudel P, Pujade-Lauraine E, Gouy S, Tredan O, Barbaza MO, Ady-Vago N, Dubot C. *Oncol Lett*. 2016 Mar;11(3):1859-1865. Epub 2016 Jan 26.

Treatment of Advanced Renal-Cell Carcinoma. Huillard O, Alexandre J, Goldwasser F. *N Engl J Med*. 2016 Mar 3;374(9):888. doi: 10.1056/NEJMc1515613. No abstract available.

[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. Bretagne M, Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J, Tlemsani C, Cessot A, Cabanes L, Blanchet B, Coriat R, Alexandre J, Goldwasser F. *Bull Cancer*. 2016 Mar;103(3):259-72. doi: 10.1016/j.bulcan.2015.10.020. Epub 2016 Jan 29. Review. French.

Angiotensin System Inhibitors in Renal Cell Carcinoma--Letter. Huillard O, Xylinas E, Peyromaure M, Alexandre J, Goldwasser F. *Clin Cancer Res*. 2016 Jan 15;22(2):524. doi: 10.1158/1078-0432.CCR-15-2102. No abstract available.

Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study. Falandry C, Horard B, Bruyas A, Legouffe E, Cretin J, Meunier J, Alexandre J, Delecroix V, Fabbro M, Certain MN, Maraval-Gaget R, Pujade-Lauraine E, Gilson E, Freyer G. *Aging (Albany NY)*. 2015 Dec;7(12):1066-76.

Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. Ajgal Z, Chapuis N, Emile G, Cessot A, Tigaud JM, Huillard O, Boudou-Rouquette P, Fontenay M, Goldwasser F, Alexandre J. *Cancer Chemother Pharmacol*. 2015 Nov;76(5):1033-9. doi: 10.1007/s00280-015-2875-8. Epub 2015 Sep 29.

Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decision-Making. Huillard O, Colombet I, Montheil

V, Weiler F, Boudou-Rouquette P, Arrondeau J, Tlemsani C, Cessot A, Giroux J, Alexandre J, Goldwasser F, Vinant P. *Oncologist*. 2015 Sep;20(9):e26. doi: 10.1634/theoncologist.2015-0131. Epub 2015 Aug 7. No abstract available.

A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. Belleville T, Noé G, Huillard O, Thomas-Schoemann A, Vidal M, Goldwasser F, Alexandre J, Blanchet B. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2015 May 1;989:86-90. doi: 10.1016/j.jchromb.2015.03.001. Epub 2015 Mar 9.

Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, Thomas-Schoemann A, Coriat R, Durand JP, Giroux J, Alexandre J, Goldwasser F. *Expert Opin Drug Metab Toxicol*. 2015 May;11(5):785-94. doi: 10.1517/17425255.2015.1030392. Epub 2015 Mar 25. Review.

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, Cupissol D, Selle F, Isambert N, Piperno-Neumann S, Thyss A, Bertucci F, Bompas E, Alexandre J, Collard O, Lavau-Denes S, Soulié P, Toulmonde M, Le Cesne A, Lacas B, Duffaud F; French Sarcoma Group. *Lancet Oncol*. 2015 Apr;16(4):457-64. doi: 10.1016/S1470-2045(15)70070-7. Epub 2015 Mar 18.

Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, Thomas-Schoemann A, Vidal M, Tigaud JM, Durand JP, Alexandre J, Goldwasser F. *Expert Opin Investig Drugs*. 2015 May;24(5):673-87. doi: 10.1517/13543784.2015.1005736. Epub 2015 Jan 20. Review.

Gynecologic Cancer InterGroup (GFIG) consensus review for mucinous ovarian carcinoma. Ledermann JA, Luvero D, Shafer A, O'Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J, Oza A, Brown J. *Int J Gynecol Cancer*. 2014 Nov;24(9 Suppl 3):S14-9. doi: 10.1097/IGC.0000000000000296. Review.

Gynecologic Cancer InterGroup (GFIG) consensus review for squamous cell carcinoma of the ovary. Glasspool RM, González Martín A, Millan D, Lorusso D, Åvall-Lundqvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, Alexandre J, Ledermann JA. *Int J Gynecol Cancer*. 2014 Nov;24(9 Suppl 3):S26-9. doi: 10.1097/IGC.0000000000000209. Review.

Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F. *Expert Opin Drug Saf*. 2014 May;13(5):663-73. doi: 10.1517/14740338.2014.907270. Epub 2014 Apr 3. Review.

Association between high antitumor activity of oxaliplatin and cyclophosphamide and constitutional GSTM1 homozygous deletion in an advanced ovarian cancer patient. Gataa I, Emile G, Lorient MA, Goldwasser F, Alexandre J. *Chemotherapy*. 2013;59(4):290-3. doi: 10.1159/000357517. Epub 2014 Jan 24.

Treatment of ovarian anaplastic ependymoma by an aromatase inhibitor. Deval B, Rousset P, Bigenwald C, Nogales FF, Alexandre J. *Obstet Gynecol*. 2014 Feb;123(2 Pt 2 Suppl 2):488-91. doi: 10.1097/AOG.000000000000077.

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies. Goldwasser F, Faivre S, Alexandre J, Coronado C, Fernández-García EM, Kahatt CM, Paramio PG, Dios JL, Miguel-Lillo B, Raymond E. *Invest New Drugs*. 2014 Jun;32(3):500-9. doi: 10.1007/s10637-013-0060-7. Epub 2014 Jan 7.

Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. Coriat R, Alexandre J, Nicco C, Quinquis L, Benoit E, Chéreau C, Lemaréchal H, Mir O, Borderie D, Tréluyer JM, Weill B, Coste J, Goldwasser F, Batteux F. *J Clin Invest*. 2014 Jan;124(1):262-72. doi: 10.1172/JCI68730. Epub 2013 Dec 20.

Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network. Maillet D, Goulvent T, Rimokh R, Vacher-Lavenu MC, Pautier P, Alexandre J,

Pujade-Lauraine E, Devouassoux-Shisheboran M, Treilleux I, Ray-Coquard I, Savina A. *Gynecol Oncol*. 2014 Jan;132(1):181-7. doi: 10.1016/j.ygyno.2013.10.013. Epub 2013 Oct 22.

Nutritional status is superior to the ECOG performance status in predicting the dose-intensity of the GEMOX chemotherapy regimen in patients with advanced cancer. Cessot A, Coriat R, Mir O, Boudou-Rouquette P, Giroux J, Durand JP, Alexandre J, Goldwasser F. *Nutr Cancer*. 2013;65(8):1254-7. doi: 10.1080/01635581.2013.830315. Epub 2013 Oct 7.

A new strategy to target regulatory T cells in solid tumors. Thomas-Schoemann A, Batteux F, Alexandre J. *Oncoimmunology*. 2013 Mar 1;2(3):e23338.

A clinical experience of single agent bevacizumab in relapsing ovarian cancer. Emile G, Chauvenet L, Tigaud JM, Chidiac J, Pujade Lauraine E, Alexandre J. *Gynecol Oncol*. 2013 Jun;129(3):459-62. doi: 10.1016/j.ygyno.2013.02.035.

A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Weber B, Largillier R, Ray-Coquard I, Yazbek G, Meunier J, Alexandre J, Dauba J, Spaeth D, Delva R, Joly F, Pujade-Lauraine E, Copel L; GINECO group, France. *Support Care Cancer*. 2013 Jul;21(7):1947-54. doi: 10.1007/s00520-013-1748-0. Epub 2013 Feb 19.

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Trédan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J, Ray-Coquard I. *Target Oncol*. 2013 Dec;8(4):243-51. doi: 10.1007/s11523-012-0242-9. Epub 2012 Dec 13.

Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy. Coriat R, Boudou-Rouquette P, Durand JP, Forgeot d'Arc P, Martin I, Mir O, Ropert S, Alexandre J, Goldwasser F. *J Oncol Pract*. 2012 Jul;8(4):205-10. doi: 10.1200/JOP.2011.000447. Epub 2012 Jun 5.

Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer. Thomas-Schoemann A, Batteux F, Mongaret C, Nicco C, Chéreau C, Annereau M, Dauphin A, Goldwasser F, Weill B, Lemare F, Alexandre J. *J Immunol*. 2012 Dec 1;189(11):5171-7. doi: 10.4049/jimmunol.1103094. Epub 2012 Oct 26.

Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patients. Colombet I, Montheil V, Durand JP, Gillaizeau F, Niarra R, Jaeger C, Alexandre J, Goldwasser F, Vinant P. *BMJ Support Palliat Care*. 2012 Sep;2(3):239-47. doi: 10.1136/bmjspcare-2011-000157. Epub 2012 Jun 30.

Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Coriat R, Nicco C, Chéreau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux F. *Mol Cancer Ther*. 2012 Oct;11(10):2284-93. doi: 10.1158/1535-7163.MCT-12-0093. Epub 2012 Aug 17.

Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. Mir O, Boudou-Rouquette P, Giroux J, Chapron J, Alexandre J, Gibault L, Ropert S, Coriat R, Durand JP, Burgel PR, Dusser D, Goldwasser F. *Lung Cancer*. 2012 Jul;77(1):104-9. doi: 10.1016/j.lungcan.2012.01.014. Epub 2012 Feb 24.

A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer. Lortholary A, Hardy-Bessard AC, Bachelot T, de Rauglaudre G, Alexandre J, Bourgeois H, Jaubert D, Paraiso D, Largillier R. *Breast Cancer Res Treat*. 2012 Jan;131(1):127-35. doi: 10.1007/s10549-011-1776-8. Epub 2011 Sep 24.

An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Mir O, Coriat R, Cabanes L, Ropert S, Billemonet B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B, Goldwasser F. *Oncologist*. 2011;16(9):1325-32. doi: 10.1634/theoncologist.2010-0002. Epub 2011 Aug 1.

[Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study]. Thomas-Schoemann A, Alexandre J, Mongaret C, Azibi S, Dauphin A, Goldwasser F, Lemare F. *Bull Cancer*. 2011 Jun;98(6):645-53. doi: 10.1684/bdc.2011.1375. French.

Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients. Mir O, Alexandre J, Coriat R, Ropert S, Boudou-Rouquette P, Bui T, Chapron J, Durand JP, Dusser D, Goldwasser F. *Invest New Drugs*. 2012 Aug;30(4):1756-60. doi: 10.1007/s10637-011-9690-9. Epub 2011 May 26.

CXCL12 expression by healthy and malignant ovarian epithelial cells. Machelon V, Gaudin F, Camilleri-Broët S, Nasreddine S, Bouchet-Delbos L, Pujade-Lauraine E, Alexandre J, Gladieff L, Arenzana-Seisdedos F, Emilie D, Prévot S, Broët P, Balabanian K. *BMC Cancer*. 2011 Mar 16;11:97. doi: 10.1186/1471-2407-11-97.

Bystander effect of vinorelbine alters antitumor immune response. Thomas-Schoemann A, Lemare F, Mongaret C, Bermudez E, Chéreau C, Nicco C, Dauphin A, Weill B, Goldwasser F, Batteux F, Alexandre J. *Int J Cancer*. 2011 Sep 15;129(6):1511-8. doi: 10.1002/ijc.25813. Epub 2011 Apr 1.

[Ovarian immature teratoma during pregnancy]. Hélage S, Borghese B, Depinay C, Millischer-Bellaïche AÉ, Alexandre J, Chopin N. *Presse Med*. 2011 Jan;40(1 Pt 1):102-5. doi: 10.1016/j.lpm.2010.09.013. Epub 2010 Oct 29. French. No abstract available. Erratum in: *Presse Med*. 2011 Dec;40(12):1211. Helage, Siegfried [corrected to Hélage, Siegfried].

Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate. Joimel U, Gest C, Soria J, Pritchard LL, Alexandre J, Laurent M, Blot E, Cazin L, Vannier JP, Varin R, Li H, Soria C. *BMC Cancer*. 2010 Jul 17;10:375. doi: 10.1186/1471-2407-10-375.

Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. Mir O, Ropert S, Babinet A, Alexandre J, Larousserie F, Durand JP, Enkaoua E, Anract P, Goldwasser F. *Cancer Chemother Pharmacol*. 2010 Nov;66(6):1059-63. doi: 10.1007/s00280-010-1259-3. Epub 2010 Feb 13. PMID:20155268

Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. Coriat R, Mir O, Camps S, Ropert S, Billefont B, Leconte M, Larousserie F, Anract P, Alexandre J, Goldwasser F. *Cancer Chemother Pharmacol*. 2010 Feb;65(3):491-5. doi: 10.1007/s00280-009-1054-1. Epub 2009 Jul 9.